Objective-Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results-We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage-or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr −/− ) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. Conclusions-These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.
V ein graft failure is a global health burden with no effective medical solutions. 1 Because of the pandemic of atherosclerotic peripheral artery disease and the growing prevalence of underlying metabolic disorders, 2 the incidence of vein graft failure is rising. Although many mechanisms for arterial diseases have been established, the pathogenesis of vein graft failure remains incompletely understood. Autologous saphenous vein grafts are widely used for peripheral artery disease because they remain patent longer than artificial conduits. 3 Approximately 50% of lower extremity saphenous vein grafts, however, become occluded or narrowed within a year. 4 When peripheral artery disease grafts fail, the only available therapeutic options are devastating limb amputation or invasive and expensive angioplasty or surgical revascularization. Coronary artery saphenous vein graft also fail at high rates. 5 Although current therapies such as statins can reduce the onset of complications of arterial diseases (eg, myocardial infarction), 6 no effective medical solutions are available for vein graft failure.
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The Notch pathway, involving ligands (Delta-like ligand [Dll]1, Dll3, Dll4, Jagged1, and Jagged2) and receptors (Notch1-4), contributes to biological processes during development and to disease mechanisms in adults. 7, 8 Direct cell-tocell contract via the binding of a ligand to a Notch receptor, both of which are expressed on the cell surface, triggers downstream responses. 9 We previously demonstrated that Dll4mediated Notch signaling promotes macrophage activation. 10, 11 Clinical and preclinical evidence has established the causal role of macrophages in arterial atherosclerosis. 12, 13 Failing vein grafts also tend to contain macrophages, 2, 14 but their role in the disease progression remains unclear. To test the hypothesis that macrophage Notch signaling contributes to the pathogenesis of vein graft disease, this study used 2 clinically relevant biotherapeutics: (1) Dll4 blocking antibody and (2) Dll4 smallinterfering RNA (siRNA) encapsulated in macrophage-or endothelial cell (EC)-targeted lipid nanoparticles (LNPs).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Increased Expression of Dll4 in Macrophages in Human and Mouse Vein Grafts
In control human saphenous veins before grafting, little if any intimal cells were immunoreactive for Dll4, whereas the thickened intima of failed human saphenous vein graft contained many cells expressing Dll4 (Figures 1A; Figure I in the online-only Data Supplement). In the failed grafts, some CD68positive intimal macrophages were immunoreactive to Dll4 antibody ( Figure IB in the online-only Data Supplement). In high-cholesterol/high-fat-fed Ldlr −/− mice, IVC implanted into the carotid artery developed more advanced lesions than in wildtype mice. 15 The neointima of vein grafts in Ldlr −/− mice showed features similar to those of advanced arterial plaques prone to rupture, including foam cell accumulation, microvessels, and intraplaque hemorrhage ( Figure II in the online-only Data Supplement), supporting previous reports on a similar model in hypercholesterolemic ApoE3*Leiden mice by the Paul Quax group. 16, 17 Vein grafts of Ldlr −/− mice expressed higher levels of Dll4 mRNA compared with native IVC of Ldlr −/− or wild-type mice (quantitative polymerase chain reaction [qPCR], Figure  1B ). In mouse vein grafts, Dll4 localized primarily to intimal macrophages, whereas smooth muscle cell (SMC) expression of Dll4 was minimal (day 28, double immunofluorescence, Figure  1C ). Ligand binding promotes the cleavage of Notch receptors and release of the intracellular domain. 9 The amount of Notch1 intracellular domain (NICD), as identified by the antibody that recognizes the neoepitope, thus indicates the levels of Notchsignaling activation. NICD accumulated primarily in intimal macrophages of vein grafts 28 days after implantation, whereas few if any SMC and EC were stained positively ( Figure III 
Blockade of Dll4 Reduces Lesion Formation and Inflammation in Vein Grafts
Blocking antibody for Dll4 11, 18, 19 was administered to Ldlr −/− mice twice a week for 28 days. Reduced amounts of NICD after antibody administration indicate that Dll4 mediates Notch activation in vein graft lesions ( Figure 1D ). Dll4 blockade produced . We previously verified that administration of the same antibody for 3 months did not affect blood pressure, food consumption, and physical activity in Ldlr −/− mice. 11 Histological assessment demonstrates that 28 days of Dll4 antibody treatment decreased the area and thickeness of the intima of vein grafts in Ldlr −/− mice but produced no significant changes in the lumen diameter, media/adventitia thickness, or vessel diameter ( Figure 2A ). Noninvasive ultrasonography is routinely used to monitor the patency of To examine whether Dll4 plays a major pathological role in the early processes of venous responses to the arterial environment and ask a more clinical question whether a shorter antibody administration after surgery is also effective, we administered Dll4 antibody only for 7 days after graft implantation. This 1-week Dll4 blockade did not reduce lesion size at day 28 ( Figure VIIA in the online-only Data Supplement). It should be noted, however, that this short treatment produced a statistically significant reduction of intimal macrophage accumulation, which was sustained until 21 days later (day 28) without continued antibody administration ( Figure VIIB in the online-only Data Supplement). We previously reported that Dll4 blockade for 12 weeks improves glucose tolerance and insulin sensitivity. 11 As demonstrated in the present study, Dll4 blockade for 7 or 28 days significantly reduced macrophage accumulation in vein grafts. To address whether improved glucose metabolism may have contributed to the beneficial effects of Dll4 suppression on vein grafts, we examined glucose tolerance and insulin sensitivity 7 days after the initiation of antibody administration. Seven-day Dll4 antibody treatment caused no effects on these metabolic parameters ( Figure VIII in the online-only Data Supplement).
We further examined the effects of Dll4 suppression on the inflammatory burden in vein grafts. Dll4 antibody-treated vein grafts contained lower levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and PDGF-B mRNA compared with control grafts ( Figure 3A ). To examine whether the reduced expression of these factors merely resulted from diminished macrophage number, or whether Dll4 blockade also reduced macrophage activation, we performed qPCR on macrophages isolated from vein grafts. Dll4 antibody treatment decreased macrophage expression of IL-1β and TNFα, molecules typical of a proinflammatory M1 phenotype ( Figure 3B ). 13 In contrast, Dll4 antibody therapy increased arginase 1 that represents non/anti-inflammatory M2 polarization ( Figure 3B ). A reduction of Hey2, a prototypical Notch target gene, indicates that Dll4 antibody indeed suppressed Notch signaling in macrophages. These results indicate that Dll4 suppression diminishes the proinflammatory microenvironment in vein grafts.
Dll4 Blockade Suppresses MMP Activity and Reduces Thin Collagen Fibers
In vivo molecular imaging further assessed the effects of Dll4 suppression on macrophage activation in vein grafts. We coinjected 2 imaging agents that elaborate near-infrared signals to visualize macrophage phagocytic activity (AminoSPARK, 750 nm) and MMP activity (MMPSense, 680 nm). Dll4 blockade inhibited macrophage phagocytic activity and MMP activity in parallel ( Figure 4A ). Notably, Dll4 antibody therapy reduced macrophage activation in vein grafts as early as 7 days after implantation, supporting our microscopic observation ( Figure VII in the online-only Data Supplement). MMP produced by activated macrophages impair collagen content and structures. 12, 22 Picrosirius red staining viewed under a circularly polarized microscope showed no significant difference in the content of total fibrillar collagen between 2 groups ( Figure 4B ). Collagen hue analysis, however, revealed that Dll4 blockade decreased thin collagen fiber ( Figure 4B ), indicating that collagen degradation by macrophage-derived proteolytic activity may have reduced. vivo. 25, 26 In pilot experiments, a single injection of 0.5 mg/ kg C12-200-siDll4 resulted in a 51% reduction of Dll4 mRNA in splenic macrophages in 72 hours ( Figure 5A ).
Macrophage-Targeted Dll4 Silencing Inhibits Intimal Thickening and Macrophage Accumulation
To validate the selectivity of Dll4 silencing to macrophages in vivo, we administered 0.5 mg/kg C12-200-siDll4 at 21 and 24 days after vein graft implantation. qPCR of intimal tissues containing endothelium or macrophage clusters isolated by laser capture microdissection showed inhibition of Dll4 expression in vein graft macrophages by >70%, but no effect in endothelium ( Figure 5B ). C12-200-siDll4 was then injected at 0.5 mg/kg, twice a week, in Ldlr −/− mice. C12-200-siDll4 decreased intimal area and thickness as compared with control C12-200 containing nontargeting siRNA ( Figure 5C ). C12-200-siDll4 reduced macrophage accumulation in the intimal layer (Figure 5D ), although it did not significantly increase thick collagen fibers ( Figure 5E ). These results indicate that Dll4 expressed by macrophages contributes to the lesion formation and macrophage burden in vein grafts.
Dll4 Regulates Expression of Proinflammatory Molecules in Macrophages
To explore mechanistic evidence for the causal role of Dll4 in macrophage activation, we performed gain-of-function and loss-of-function experiments in mouse primary macrophages. Transient overexpression of Dll4 induced prototypical Notch target genes Hes1 and Hey1 ( Figure 6A ). Enforced expression of Dll4 induced proinflammatory molecules typical of M1 macrophages (eg, IL-1β, TNF-α; Figure 6B ). In contrast, Dll4 blocking antibody exerted opposing effects ( Figure 6C ). Furthermore, Dll4 blockade inhibited the expression of proinflammatory genes iNOS and TNF-α induced by IFN-γ, a typical M1 stimulation ( Figure 6D ). These in vitro findings are consistent with in vivo data shown in Figure 3 .
Macrophage Dll4 Promotes SMC Migration, Proliferation, and dedifferentiation
SMC migration and proliferation may contribute to the development of vein graft lesions. 21 Notch signaling requires the direct cell-cell contact via the ligand-receptor binding. SMCs in the intima of atherosclerotic plaques and vein grafts are, however, surrounded by extracellular matrix and generally lack membrane contacts with neighboring SMCs, whereas such direct contacts are common in plaque macrophages, 14, 27, 28 suggesting that direct physical interactions between SMC and macrophages via Dll4-Notch binding may hardly occur. Nevertheless, we examined the effects of Dll4 binding to SMC in vitro using primary human saphenous vein SMC. Immobilized recombinant Dll4 attachment did not affect the number of human saphenous vein SMCs both in 0.5% and 10% fetal bovine serum ( Figure IXA in the online-only Data Supplement). Blockade of Dll4 binding also produced no effects on the growth of human saphenous vein SMC ( Figure IXB in the online-only Data Supplement). These results indicate that direct Dll4 binding may not play a major role in SMC biology. Therefore, we performed indirect coculture experiments to examine whether macrophage expression of Dll4 induces SMC migration, proliferation, and dedifferentiation by soluble factors in a paracrine fashion. Conditioned media from RAW264.7 cells transfected with Dll4 plasmid accelerated SMC migration ( Figure 7A ), increased SMC number ( Figure 7B) , and suppressed their expression of myosin heavy chain, the strictest SMC differentiation marker ( Figure 7C ). 29 PDGF-BB induces SMC migration, proliferation, and dedifferentiation. 30, 31 Notch activation by enforced expression of Dll4 or immobilized recombinant Dll4 induced PDGF-B expression in RAW264.7 cells ( Figure 7D and 7E) , indicating that PDGF-BB may mediate the effects of Dll4 via macrophage-SMC crosstalk. Other proinflammatory factors, which Dll4 induces in macrophages, may also contribute to this interaction ( Figure 6 ).
Role of EC-Derived Dll4 in the Development of Vein Graft Lesions
Among human primary macrophages, human saphenous vein SMC, and human saphenous vein EC, Dll4 mRNA levels were highest in human saphenous vein EC under the quiescent state ( Figure We therefore explored a new mechanism, by which EC-derived Dll4 participates in the pathogenesis of vein graft disease using Dll4 siRNA formulated in EC-targeted LNP 7C1 (7C1-Dll4 siRNA). 32 Dll4 silencing by 7C1-Dll4 siRNA reduced Dll4 mRNA in endothelium by >70% ( Figure 8A ). Despite the high silencing efficacy, EC-targeted Dll4 suppression produced no effects on several parameters for the development of vein graft lesions (intima area, intima thickness, lumen diameter, media/ intima thickness, and vessel diameter; Figure 8B and 8C) . These results further support a major role for macrophage Dll4 in vein graft disease.
Discussion
Although many mechanisms have been proposed and validated for arterial diseases, the pathogenesis of vein graft disease remains obscure. Using 2 different biotherapies-blocking antibody and macrophage-targeted siRNA, this study demonstrates novel mechanisms by which macrophage Dll4 promotes the development of vein graft lesions. Accumulating evidence has established that macrophages contribute to various mechanisms for arterial diseases, including plaque rupture. 6, 12, 13 The role of macrophages in vein graft disease, however, remains elusive. Failing vein grafts in patients exhibit macrophage accumulation 14 and signs of rupture. 33, 34 Clinical evidence has linked biomarkers of inflammation with vein graft failure. 35 Preclinical studies proposed the role of macrophages in neointima formation in vein grafts. 16, 36, 37 However, no medical therapies are currently available to target vein graft inflammation, which has driven our current efforts.
The key novel findings demonstrated in this study include (1) the expression of Dll4 by macrophages in the intima of human and mouse vein grafts; (2) increased Dll4 expression and NICD accumulation during the development of experimental vein graft lesions; (3) positive correlations between the graft wall area and Dll4 expression or NICD accumulation; (4) reduced vein graft lesions after Dll4-targeted biotherapeutics (blocking antibody and macrophage-selective Dll4 siRNA); (5) the role of Dll4-Notch signaling in macrophage and SMC growth in vein grafts; (6) the effects of Dll4 blockade on macrophages being independent of metabolic effects; (7) the potential role of Dll4 in EC activation; (8) no substantial in vivo role for EC-derived Dll4 in vein graft disease as demonstrated by EC-targeted Dll4 siRNA; and (9) the role of Dll4-expressing macrophages in SMC dedifferentiation, migration, and proliferation via a paracrine mechanism.
The previous studies including our own suggested that Notch-signaling components, including Dll4, contribute to various biologies of hematopoietic cells. 10, 11, [38] [39] [40] [41] [42] [43] However, the mechanistic evidence for the role of Dll4 in inflammation of cardiovascular organs remains scant. 10, 11 Macrophage polarization, as often classified by at least 2 subpopulations: a proinflammatory (M1) and an anti/noninflammatory (M2), is associated with various cardiovascular diseases. 13, 44 In vein grafts, Dll4 blockade reduced the expression of multifunctional proinflammatory IL-1β and TNF-α, typical M1 molecules, suggesting the broad antiatherogenic effects of Dll4 antibody via suppression of a positive feedback loop of sustained macrophage activation and providing insight into the clinical impact of this therapy. Examining the relative contribution of macrophage-derived Dll4 used the macrophagetargeted LNP C12-200. Dll4 silencing in macrophages via C12-200 decreased intimal thickening and macrophage burden.
Our in vitro evidence in this study suggests a role for Dll4 in EC activation. Therefore, we used EC-targeted LNP 7C1 to explore an additional potential mechanism for vein graft disease mediated by EC-derived Dll4. Despite an excellent silencing efficacy in endothelium, Dll4 siRNA formulated in 7C1 produced no effects on the development of vein graft lesions, as quantitatively determined by several parameters. These results provide another line of evidence for the pivotal role of Dll4 expressed by macrophages in the development of inflamed vein grafts.
Phenotypic modulation of SMC contributes to the pathogenesis of arterial diseases. 29 SMC activation may also participate in the pathogenesis of vein graft disease. 21 This study therefore explored the novel mechanism that Dll4 in SMC promotes activation of this vascular cell type. Dll4 expression levels were, however, much lower in quiescent or activated primary human SMC than those in macrophages or EC. Dll4 binding to primary SMC did not induce their proliferation. In addition, previous studies demonstrated a lack of membrane contact between SMC surrounded by extracellular matrix, whereas direct contact between macrophages is common. 27, 28 Notch-signaling activation requires direct cell-to-cell contact that allows ligand-receptor binding. Thus, Dll4-Notch interaction between neighboring SMC or between SMC and macrophages may not occur so frequently in vascular lesions. Instead, a series of experiments reported in this study suggest a novel paracrine mechanism by which macrophage Dll4 activates neighboring SMC ( Figure XIIA in the online-only Data Supplement).
To maximize clinical significance of our study, we used 2 scientifically validated and clinically relevant techniques to suppress Dll4-RNAi mediated by LNP and antibody administration. The gene silencing by siRNA oligos formulated in LNP, a robust and well-established research tool for investigating the role of macrophage gene expression in vivo, enabled us to selectively target Dll4 in macrophages or EC, as documented in the previous studies. 25, 26, 32, 45, 46 It should be noted that the delivery of siRNA in such LNP has already been used in humans and proven safe and effective, contributing to the generation of promising clinical data. [47] [48] [49] In addition, antibody therapies for chronic diseases have become widely available in the clinic. For instance, a phase IIb clinical trial on 4 months of anti-IL-1β monoclonal antibody treatment presented anti-inflammatory effects (eg, reductions in C-reactive protein levels) with no substantial adverse effects, 50 leading to a longer, larger cardiovascular outcome study. In the present study, Dll4 antibody therapy for only 7 days exerted beneficial effects on lesional macrophages in vein grafts. The use of such clinically relevant therapeutics suggests how our preclinical findings could be translated into the clinical development of Dll4-targeted therapies for vein grafts. In addition, noninvasive ultrasonography of vein grafts, a routine procedure in the clinic, in live mice supports the microscopic findings. These lines of evidence indicate the clinical translatability of our mouse study.
In conclusion, we provide the novel evidence that the Dll4-Notch axis contributes to the pathogenesis of vein graft lesion development ( Figure XIIA 
